Adamas Announces New Employment Inducement Grant
November 08 2019 - 4:01PM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that
the compensation committee of the company’s board of directors
granted three new employees the option to purchase an aggregate of
14,500 shares of the company’s common stock, at a per share
exercise price of $4.70, the closing trading price on November 7,
and restricted stock units to acquire 7,250 shares of the company’s
common stock. The stock options and restricted stock units vest
over four years and were granted pursuant to the Adamas
Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by
the company's board of directors in March 2016 under Rule
5653(c)(4) of the Nasdaq Global Market for equity grants to induce
new employees to enter into employment with the company.
About Adamas Pharmaceuticals,
Inc. Adamas’ goal is to create and commercialize a
new generation of medicines intended to lessen the burden of
chronic neurologic diseases on patients, caregivers and society
using its deep understanding of time-dependent biology. The Company
is focused on the commercialization of GOCOVRI® (amantadine)
extended release capsules, the first and only FDA-approved medicine
for the treatment of dyskinesia in patients with Parkinson’s
disease receiving levodopa-based therapy, with or without
concomitant dopaminergic medications. The Company also continues to
deliver differentiated investigational programs, including ADS-5102
in development for the treatment of walking impairment in patients
with multiple sclerosis. For more information about Adamas and its
unique approach to developing medicines based on time-dependent
biology, please visit www.adamaspharma.com.
Contact:
Investors:Peter VozzoWestwicke Partners
443-213-0505peter.vozzo@westwicke.com
Media: Sarah MathiesonVice President,
Communications & Engagement
510-450-3528smathieson@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Apr 2023 to Apr 2024